Stopping GLP-1 drugs like Ozempic erodes heart health benefits quickly, new study finds

People who stop taking popular weight-loss and diabetes medications may lose out on any heart health benefits the medications provided.

GLP-1 receptor agonists — such as semaglutide (Ozempic and Wegovy), and tirzepatide (Mounjaro and Zepbound) — have been shown to reduce the risk of heart attack and stroke.

A new study from the Washington University School of Medicine in St. Louis explored the effects of quitting — particularly related to cardiovascular health.

NEW OZEMPIC-ALTERNATIVE...